CJC-1295 with DAC vs without DAC: how the two forms differ
The short version: same peptide backbone, very different half-life.
TL;DR
- CJC-1295 comes in two forms: with DAC and without DAC. The science is the same; the staying power is different.
- In a study in healthy adults, the DAC form stayed active for about a week. The form without DAC is cleared within minutes.
- The research describes how each form behaves in the body. It does not show that either form is safe or effective for any use.
What it is
CJC-1295 is a synthetic version of GHRH (in plain English: growth hormone-releasing hormone, the body's signal that tells the pituitary gland to release growth hormone). It comes in two forms. Without DAC, it is essentially modified GRF 1-29, a short-acting GHRH analog. With DAC (in plain English: a Drug Affinity Complex, a small chemical clip added to the molecule), the peptide binds to albumin (a common blood protein) and circulates for days instead of minutes (Teichman et al., J Clin Endocrinol Metab, 2006).
How it works
Think of GHRH like a doorbell at the pituitary gland. The body normally rings that doorbell in short, repeated pulses through the day. CJC-1295 without DAC presses the bell once and then disappears, mimicking one natural pulse. In the study described below, CJC-1295 with DAC acted more like a magnet clipped to your finger, so the bell kept ringing softly for about a week. Both ring the same doorbell — the GHRH receptor — but the rhythm is different. The pituitary then releases growth hormone in response.
Who asks about it
People come to this question when they have read about CJC-1295 and noticed the same name keeps appearing in two different forms, with different half-lives and different warnings. The confusion is fair. The two forms are made from the same peptide backbone but behave very differently in the body.
What the research says
A 2006 study in healthy adults showed CJC-1295 with DAC raised growth hormone and IGF-1 (in plain English: insulin-like growth factor 1, a downstream marker of growth hormone activity) for up to 11 days after a single injection (Teichman et al., 2006). The without-DAC form has no albumin-binding piece, so it does not last long in the blood and produces only a brief growth-hormone pulse. With the DAC form, a follow-up study found that GH kept its natural pulses during continuous stimulation, while trough GH levels rose about 7.5-fold (Ionescu and Frohman, J Clin Endocrinol Metab, 2006). Mild facial flushing has been reported with the long-acting form.
What the research does not show
Neither form is FDA-approved. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list. The human studies were short-term and measured hormone levels, not long-term safety or health outcomes. The longer half-life of the DAC form also means any side effect can last longer.
The Halftime POV
The DAC-vs-no-DAC question gets framed as "which is better" online. The research answers a narrower question: how long each form stays in the blood, and what that does to growth hormone levels in short studies. That is useful to understand. It is not evidence that either form is safe or useful for anyone.
Related reading:
- CJC-1295: what this modified GHRH peptide is
- How CJC-1295 extends GHRH signaling: the mechanism
- Peptide half-life basics: why some peptides last longer than others
FAQ
Q: What does DAC mean in CJC-1295? A: DAC stands for Drug Affinity Complex. It is a small chemical attachment that lets the peptide bind to albumin in the blood, which extends how long the molecule stays active from minutes to about a week.
Q: Is CJC-1295 with DAC better than without? A: Research does not show that either form is better. In a study in healthy adults, the DAC form raised growth hormone for about a week, mostly by lifting levels between the body's natural pulses. The form without DAC is short-acting and produces a brief pulse. Neither form has been shown to be safe or effective for any use.
Q: Is CJC-1295 FDA-approved? A: No. CJC-1295 in either form is not FDA-approved as a finished drug product. Compounded CJC-1295 is not FDA-approved. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Sources
- Teichman SL et al. — J Clin Endocrinol Metab, 2006: Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295
- Ionescu M, Frohman LA — J Clin Endocrinol Metab, 2006: Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What does DAC mean in CJC-1295?
DAC stands for Drug Affinity Complex. It is a small chemical attachment that lets the peptide bind to albumin in the blood, which extends how long the molecule stays active from minutes to about a week.
Is CJC-1295 with DAC better than without?
Research does not show that either form is better. In a study in healthy adults, the DAC form raised growth hormone for about a week, mostly by lifting levels between the body's natural pulses. The form without DAC is short-acting and produces a brief pulse. Neither form has been shown to be safe or effective for any use.
Is CJC-1295 FDA-approved?
No. CJC-1295 in either form is not FDA-approved as a finished drug product. Compounded CJC-1295 is not FDA-approved. As of September 14, 2026, CJC-1295 is not in any FDA 503A category and is not on the 503A bulks list.
